EMA adopts new policies on conflicts of interest, access to documents
This article was originally published in SRA
The European Medicines Agency will publish shortly two long-awaited new policies on how the agency should manage conflicts of interest of its scientific committee experts and how it should allow better public access to EMA documents1.
You may also be interested in...
Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers.
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.